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Adventitial delivery of platelet-derived endothelial
cell growth factor gene prevented intimal
hyperplasia of vein graft
Mitsuteru Handa, MD, Wei Li, MD, PhD, Kouichi Morioka, MD, PhD, Atsushi Takamori, MD,
Narihisa Yamada, MD, PhD, and Akio Ihaya, MD, PhD, Fukui, Japan
Background: Platelet-derived endothelial cell growth factor (PD-ECGF), also known as thymidine phosphorylase (TP)
reportedly inhibits vascular smooth muscle cells (VSMCs) migration and proliferation. We hypothesized that adventitial
administration of the PD-ECGF/TP gene will suppress intimal hyperplasia and prevent vein graft failure.
Methods: The study used 68 female rabbits. Rabbit jugular vein was autogenously transplanted into carotid artery with a
cuff anastomotic technique. To define vascular wall gene transfer efficiency, poloxamer hydrogel (20%) containing
plasmid vector encoding the LacZ gene and different concentrations of trypsin (0%, 0.1%, 0.25%, and 0.5%, n 5 for each
group) was applied to the adventitia of the vein graft. Gene transfer efficiency was evaluated 7 days later by X-gal staining.
An additional 48 rabbits received poloxamer hydrogel (20%) containing 0.25% trypsin and the human PD-ECGF/TP
gene, LacZ gene, or saline. Intima thickness was evaluated at 2 and 8 weeks after grafting (n  8 for each group at each
time point). Transgene expression was examined by reverse transcriptase-polymerase chain reaction, immunoblotting
assay, and immunohistochemical staining. Immunohistochemical staining was also used to determine VSMC prolifera-
tion, heme oxygenase-1 expression, and macrophage infiltration.
Results: Incorporation of trypsin into the poloxamer hydrogel significantly increased vessel wall gene transfer. Trypsin at
0.25% and 0.5% resulted in higher gene transfer at the same level without effecting intimal hyperplasia and inflammation;
thus, trypsin at 0.25% concentration was used for subsequent experiments. Compared with the LacZ and saline groups,
grafts receiving the PD-ECGF/TP gene significantly reduced intimal thickness at 2 and 8 weeks after treatment. The ratio
of proliferative VSMC was lower in PD-ECGF/TP treated grafts. Histologic examination of the PD-ECGF/TP transgene
grafts demonstrated high expression of heme oxygenase-1, which has been reported to inhibit VSMC proliferation,
suggesting that heme oxygenase-1 may be important in the inhibition effect of PD-ECGF/TP on VSMC. No neoplastic
or morphologic changes were found in the remote organs.
Conclusions: A safe and highly efficient gene transfer method was developed by using poloxamer hydrogel and a low
concentration of trypsin. Neointimal hyperplasia was significantly reduced by adventitial application of the PD-ECGF/TP
gene to the vein graft. Our data suggest that adventitial delivery of the PD-ECGF/TP gene after graftingmay be promising
method for preventing vein graft failure. ( J Vasc Surg 2008;48:1566-74.)
Clinical Relevance:Vein graft failure caused by intimal hyperplasia limits the benefits of vein grafting. Various treatments
have been examined to reduce intimal thickness, but a standard clinical treatment has not yet been established. We report
the inhibitory effect of the gene expressing platelet-derived endothelial cell growth factor/thymidine phosphorylase
(PDEGF/TP) on the development of vein graft intimal thickness with a novel hydrogel painting method. This could lead
to a new therapeutic strategy for prevention of vein graft failure, and is easy to perform during bypass surgery.Surgical bypass of arterial occlusions using autogenous
vein grafts provides an effective treatment for many patients
with advanced coronary or peripheral atherosclerosis.1
However, the long-term benefit of bypass surgery is limited
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1566by the development of de novo occlusive lesions within the
vein graft that occurs in a significant percentage of patients,
with a patency rate of nearly 85% at first year and 60% at 10
years.2 Vein bypass grafts normally undergo structural
changes characterized by the formation of a proliferative
neointima and a thickened vessel wall, resulting in a reduc-
tion in wall tension as an adaptive response to the arterial
environment. When limited, this response may lead to
stable architecture and long-term graft function. However,
progression of the proliferative response may eventually
compromise the lumen as well as render the blood vessel
increasingly susceptible to atherosclerosis. The final result
of intimal hyperplasia is thrombotic graft occlusion.3
Many factors are believed to contribute to the forma-
tion of intimal hyperplasia, including hemodynamic forces,
endothelial injury, inflammatory cell infiltration, growth
and coagulation factors, cytokines, and chemokines.1-5 At
the cellular level, the thickened neointima consists primarily
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erative, synthetic, and dedifferentiated phenotype. There-
fore, VSMCs have become the target cell of pharmacother-
apy, and have limited the impact of graft failure.
Two small clinical trials showed that preventing neoin-
timal hyperplasia by treatment with edifoligide (E2F decoy
oligodeoxynucleotide) was feasible, safe, and effective6,7;
however, two recently completed large clinical trials of
edifoligide in the setting of peripheral (Edifoligide for the
Prevention of Infrainguinal Vein Graft Failure [PREVENT]
III, n  1404) and coronary surgery (Prevention of Vein
Graft Failure FollowingCoronaryArteryBypassGraft Surgery
[PREVENT] IV, n 3014) indicated that edifoligide is no
more effective on any of the primary or secondary end
points.8,9 Thus, longer-term follow-up and additional re-
search are needed to determine its benefit.
Platelet-derived endothelial cell growth factor (PD-
ECGF), also known as thymidine phosphorylase (TP),
catalyzes the reversible dephosphorylation of thymidine to
thymine and 2-deoxy-D-ribose-1-phosphate, a process that
helps to maintain the nucleotide pool.10,11 PD-ECGF/TP
has been known to promote angiogenesis in vivo by stim-
ulating chemotaxis of endothelial cells and conferring resis-
tance to apoptosis induced by hypoxia.12-14 In our previous
studies, we have demonstrated that PD-ECGF/TP inhib-
ited VSMC proliferation and migration in vitro and in vivo.
The potential mechanisms may include, at least in part,
upregulation of heme oxygenase-1 (HO-1) expression and
consequently increased p27KIP1 in cultured VSMCs.15
These observations strongly suggest that PD-ECGF/TP
gene therapy might have an effect on preventing vein graft
failure by reducing intimal thickness. In the present study,
we demonstrated for the first time to our knowledge that
adventitial gene administration of PD-ECGF/TP signifi-
cantly decreased the proliferative VSMC in the hyperplastic
intima and markedly inhibited neointimal thickening of
vein graft.
MATERIALS AND METHODS
Sixty-eight female Japanese white rabbits were anesthe-
tized with an intramuscular injection of ketamine hydro-
chloride (30 mg/kg) and xylazine (5 mg/kg). Heparin
(1000 U) was administered intravenously, and the right
external jugular vein and common carotid artery were
exposed through a midline cervical incision. A 3- to 4-cm
length of external jugular vein was harvested as an ipsilateral
vein graft and grafted into the common carotid artery with
a cuff anastomotic technique, as described previously.16
Treatment and care of the animals in this study were
compliance with the “Guidelines of the Faculty of Medical
Sciences,” University of Fukui, and in conformity with the
Guide for the Care andUse of Laboratory Animals (National
Institutes of Health Publication No.85-23, Revised 1996).
To achieve the best efficiency of adventitial gene trans-
fection, 20 rabbits received 20% poloxamer F127 hydrogel
containing different concentration of trypsin (0%, 0.1%,
0.25%, and 0.5%, n 5 for each concentration), and 500 g
plasmid vector encoding the LacZ gene was “painted”around the graft vessel, including the anastomosis sites.
Gene transfection efficiency was assessed by X-gal staining
1 week later.
To determine whether PD-ECGF/TP gene transfer
into the vessel wall of the vein graft would prevent neoin-
timal hyperplasia, 16 rabbits received 20% poloxamer F127
hydrogel containing 0.25% trypsin and plasmid encoding
human PD-ECGF/TP (pCIhTP group). Rabbits receiving
the same hydrogel containing the LacZ gene (pCILacZ
group; n 16) or saline (n 16) were treated as controls.
Vein grafts, liver, spleen, kidney, and ovary were harvested
2 and 8 weeks later (n  8 for each group at each time
point), and the transgene expression was examined by
reverse transcriptase-polymerase chain reaction (RT-PCR),
immunoblotting assay, and immunohistochemical stain-
ing. Intimal hyperplasia was determined bymeasurement of
intimal thickness and areas based on van Gieson stain. Four
randomly selected sections were obtained from each graft
to examine the intimal hyperplasia.
The extent of maximal intimal thickness was measured
using Macscope software (Mitani Co, Fukui, Japan) at
eight random points in each section.17 The average of the
eight points was considered to represent the intimal thick-
ening of the section, and the average value of the four
sections was considered to represent the examined graft.
The intimal area was also calculated with Macscope in the
same manner. All examinations were performed in a
blinded manner by coauthors (K. M., N. Y.), who were not
aware of group division.
Standard immunohistochemical staining was per-
formed to examine the expression of HO-1 (Calbiochem,
SanDiego, Calif) and infiltration ofmacrophages (RAM11,
M0633, DakoCytomation, Kyoto, Japan). Double immu-
nohistochemical staining for vascular smooth muscle
-actin (1A4, M0851, DakoCytomation) and proliferative
cell nuclear antigen (PCNA, Dako) was performed to iden-
tify the proliferative smooth muscle cells. (Please see the
online supplement for detailed methods).
One-way analysis of variance was used for intergroup
comparisons and followed by an unpaired t test as appro-
priate. Results are reported as the mean  SD. A value of
P  .05 was considered statistically significant. The Fried-
man test was used for comparisons among the three groups.
Statistical calculations were done using StatView 5.0 soft-
ware (SAS Institute, Cary, NC).
RESULTS
The data analysis excluded three rabbits that died (1 in
the saline group for the 2-week experiments, and 2 in the
pCILacZ group for the 8-week experiments) during the
induction of anesthesia. All animals that recovered from
the first operation survived the entire period of observation.
No appreciable differences were noted in behavior or feed-
ing habits between among the treated groups. The vein
grafts from the pCIhTP group were all patent at both 2 and
8 weeks (both 100% patency); however, one graft from the
saline group at 2 weeks (85.7% patency) and two grafts
psin.
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occluded.
Determination of optimal gene transfer efficiency.
Gene transfer efficiency was assessed at 7 days after painting
the working solution in phosphate-buffered saline contain-
ing 20% poloxamer F127, 500 g pCILacZ, and various
concentrations of trypsin onto the adventitia of the vein
grafts. By whole-graft X-gal staining, we demonstrated that
grafts that received no trypsin solution did not show blue
coloration in the gross view (Fig 1, A), indicating that the
gene transfection efficiency was low using hydrogel only.
However, the addition of trypsin dramatically induced the
blue staining of the whole vein graft (Fig 1, B), suggesting
that including trypsin in the hydrogel significantly en-
hanced gene transfection into the vessel wall. By micro-
scopic examination of cross-sections of the vein grafts, we
further found that gene transfer based on hydrogel alone
only partially induced gene transfection in the whole vessel
layer (Fig 1, C); however, including the trypsin in the
working solution induced a maximum of about 50% trans-
fection (Fig 1, D).
By evaluating percentage of X-gal–positive cells to the
Fig 1. Determination of optimal gene transfer efficien
staining of whole vein grafts.C andD, Photomicrograph
and gene transfection (scale bars, 100 m). Panels A
containing LacZ alone; and B and D were from grafts tr
LacZ. E, The percentage of cells stained positive for La
media (IM, gray bars).*P  .01 vs 0% trypsin, and †P 
implantation is shown for different concentrations of trytotal cells in the intima and media or adventitia areasseparately, we found that the addition of trypsin in the gene
delivery solution dose dependently increased vascular wall
gene transfer efficiency (P  .01, all trypsin groups vs 0%
trypsin; and 0.25% and 0.5% vs 0.1% trypsin; Fig 1, E), and
reached a plateau in the 0.5% trypsin group (P  .84 vs
0.25%), further demonstrating that trypsin promoted gene
transfer into the vessel wall.
By elastica van Gieson stain, internal elastic lamina
consistency and intimal thickness according to different
concentration of trypsin was determined. There was no sig-
nificant difference in the internal elastic lamina disruption
among different concentration of trypsin used (data not
shown). We also did not find a difference in intimal thickness
among groups with different concentrations of trypsin (Fig 1,
F), suggesting that trypsin alone did not promote neointima
hyperplasia and the concentration used for this study did not
influence the vessel structure entirety. By immunohistochem-
ical staining for macrophages, there were no differences in
macrophage infiltration of the intimal area (0% trypsin, 2.2
0.3; 0.1% trypsin, 2.0  0.3; 0.25% trypsin, 2.1  0.3; and
0.5% trypsin, 2.2 0.4; per 400magnification fieldP .94
among groups), suggesting that the transgene transfer did not
and B, Representative gross views are shown of X-gal
ections of vein grafts 7 days are shown after implantation
C were from grafts treated with poloxamer hydrogel
with poloxamer hydrogel containing 0.25% trypsin and
shown in the adventitia (A, black bars) and intima and
s 0.1% trypsin. F, Intima thickness after 1 week of graft
Error bars indicate the standard deviation.cy. A
s of s
and
eated
cZ is
.01 vinduce significant inflammation. Because the 0.25% and 0.5%
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we selected 0.25% trypsin for the following studies.
Adventitial PD-ECGF/TP gene transfer suppressed
intimal hyperplasia of vein grafts. Intimal thickness was
determined based on elastic van Gieson stain, and represen-
tative images are shown in Fig 2,A. The intima was thinner
in the pCIhTP group (33.7  10.8 m), but it became
more than twofold thicker in the saline (73 12.3m) and
pCILacZ (80  20.9 m) groups at 2 weeks. At 8 weeks
after vein graft implantation, the intima became signifi-
cantly thicker in all groups compared with 2 weeks; how-
ever, the intimal hyperplasia was more serious in the saline
(205 19.9m) and pCILacZ groups (202.5 33.9m)
than in the pCIhTP group (77.5 13.7 m; Fig 2, B). To
further confirm this observation, neointimal areas were
determined. The whole areas of intimal hyperplasia were
significantly decreased in the pCIhTP group at both 2 and
8 weeks (Fig 2, C).
Adventitial PD-ECGF/TP gene transfer induced
Fig 2. Effects of platelet-derived endothelial cell grow
development of intimal hyperplasia of vein grafts at 2 (2W
A, Representative images show the middle portion of v
F127 hydrogel containing 0.25% trypsin and plasmid en
receiving the hydrogel containing the LacZ gene (pCIL
200 m, and the dashed line indicates the border of in
thickness and (C) intimal areas of vein grafts in saline (da
bars) groups indicated they were decreased in treated gro
vs pCILacZ and saline.HO-1 expression in vessel wall cells and inhibitedVSMC proliferation of vein grafts. By immunohisto-
chemical staining for HO-1, which has been well known to
inhibit VSMC proliferation, we found that HO-1 was
markedly expressed in the whole layer cells in the pCIhTP
group, with less expression in the saline or pCILacZ groups
(Fig 3, A), suggesting that human PD-ECGF/TP gene
transfer induced HO-1 expression in the vein graft vessel
wall. Mechanistically, it is well known that VSMC prolifer-
ation and neointimal migration are the major cause of
neointimal hyperplasia. We thus examined the PCNA index
of VSMC in the intimal area based on VSMC and PCNA
double immunohistochemical staining. As shown in Fig 3,
B, both PCNA-positive (brown stain) and VSMC-positive
(pink stain) stained cells were defined as proliferative
VSMCs, and their number and total VSMC in the same
area were determined. The ratio of proliferative VSMCs to
total VSMCs was calculated and defined as the VSMC-
PCNA index. The VSMC-PCNA index was significantly
lower in the pCIhTP group compared with the pCILacZ or
tor/thymidine phosphorylase (PD-ECGF/TP) on the
8 weeks (8W) after implantation and gene transfection.
raphs from rabbits that received saline, 20% poloxamer
g human PD-ECGF/TP (pCIhTP group), and rabbits
roup). Elastica van Gieson staining; the scale bar equals
(I) and media. Quantitative analysis of the (B) intimal
ay bars), pCILacZ (light gray bars), and pCIhTP (white
rror bars show the standard deviation; *P .01, pCIhTPth fac
) and
ein g
codin
acZ g
tima
rk gr
up. Esaline groups at 2 weeks after graft implantation (Fig 3, C),
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Transgene did not induce macrophage infiltration.
To determine whether the transgenes influence macro-
phage accumulation and induce inflammation, we per-
formed immunohistochemical staining for macrophages.
There was no significant difference in the percentage of
RAM11-positive cells in the neointimal area among the
groups at both 2weeks (pCIhTP, 1.6 0.3; pCILacZ, 1.8
0.2; saline, 1.9 0.3 per 400magnification field , P .89)
and 8 weeks (pCIhTP, 1.2  0.4; pCILacZ, 1.2  0.4; and
saline, 1.3  0.4 per 400 magnification field, P  .97).
Taken together with the 1-week data for identification of
gene transfection efficiency, our data suggest that this
poloxamer hydrogel–based gene transfer did not induce
significant inflammation in the early (1 to 2 weeks) or late
(8 weeks) phases.
Transgene expression. Two weeks after gene trans-
Fig 3. Assessment of heme oxygenase-1 expression and va
grafts.A, Immunohistochemical staining for heme oxygena
histochemical staining for proliferative cell nuclear antigen
arrowheads indicate the double positively stained VSMCs,
media. Scale bar equals 100m.C,Quantitative analysis of
at 2 and 8 weeks from rabbits that received saline, 20% po
encoding human platelet-derived endothelial cell growth
receiving the hydrogel containing the LacZ gene (pCILa
pCIhTP vs pCILacZ and saline.fection, human PD-ECGF/TP messenger RNA was de-tected from the vein grafts in seven of the eight rabbits in
the pCIhTP group by RT-PCR (Fig 4, A), but not in the
saline or pCILacZ groups, nor or in any group at 8 weeks
after gene transfection. Similarly, the LacZ gene was de-
tected by RT-PCR at 2 weeks in the pCILacZ group, but
not in pCIhTP and saline groups, or at 8 weeks after gene
delivery (Fig 4, B). No human PD-ECGF/TP gene or LacZ
gene expression was detected from the spleen (Fig 4, B,
spleen from LacZ group), liver, kidney, and ovary by RT-
PCR (data not shown).
Parallel to the assessment of gene expression, the immu-
noblotting assay demonstrated the expression of PD-
ECGF/TP in the vein graft was significantly higher in
pCIhTP group than in the saline or pCILacZ groups 2 weeks
after gene transfection (Fig 4, C). There was no detectable
PD-ECGF/TP expression 8 weeks after gene transfection
(data not shown), suggesting that transgene-induced PD-
ECGF/TP overexpression was too low to be determined by
smoothmuscle cell (VSMC) proliferation index in the vein
brown) and (B) representative images of double immuno-
A; brown) and VSMCs (pink) at 2 weeks are shown. The
the dashed line indicates the border of the intima (I) and
tio of PCNA-positive cells in the intimal areas of vein graphs
er F127 hydrogel containing 0.25% trypsin and plasmid
r/thymidine phosphorylase (pCIhTP group), and rabbits
oup). Error bars show the standard deviation; *P  .01,scular
se-1 (
(PCN
and
the ra
loxam
facto
cZ grWestern blot analysis 8 weeks later.
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body (a gift from Roche Japan) further confirmed the
overexpression of human PD-ECGF/TP in the whole layer
of the vein graft at 2 weeks (Fig 4, D), but almost no
expression was detected at 8 weeks (Fig 4, E). Immunohis-
tochemical staining did not find the presence of human
PD-ECGF/TP in the spleen, liver, kidney, or ovary (data
not shown) at the 2 and 8 weeks points, suggesting that this
Fig 4. Identification of transgene expression. Total RNA was
extracted from vein graft or spleen and reverse transcriptase-
polymerase chain reaction (RT-PCR) assay was performed for (A)
human platelet-derived endothelial cell growth factor/thymidine
phosphorylase (PD-ECGF/TP) in grafts at 2 and 8 weeks, or (B)
the LacZ gene in grafts and spleen at 1, 2, and 8 weeks. RT-PCR
assay for rabbit -actin was examined as an RNA quality and
loading control. C, Immunoblotting analysis of human PD-
ECGF/TP protein 2 weeks after graft implantation. Actin was
reblotted as a loading control in the same membrane. D and E,
Immunohistochemical staining for human PD-ECGF/TP in the
rabbits that received 20% poloxamer F127 hydrogel containing
0.25% trypsin and PD-ECGF (pCIhTP) group at (D) 2 weeks and
(E) 8 weeks after operation (200 magnification). Cells stained
positive for PD-ECGF/TP are brown, and arrowheads indicate
representative staining.local gene delivery system did not induce detectable level ofgene expression in the remote organs. Furthermore, we did
not find any abnormal changes such as neoplasm in these
remote organs by hematoxylin and eosin staining (data not
shown).
X-gal staining of tissue sections prepared from the
pCILacZ group demonstrated that the LacZ gene was
expressed in the whole layer of the vein graft at 2 weeks, but
almost no expression was found at 8 weeks (data not
shown). Very little LacZ expression was found in the liver,
but no expression in kidney and ovary. However a large
amount of LacZ was examined in the spleen at 2 weeks and
a mild amount was found at 8 weeks, suggesting that spleen
can trap the LacZ protein (Fig E1, online only). This is
identical with previous findings.18
DISCUSSION
This study revealed three novel findings in the area of
surgical and gene-transfer manipulations of vein grafts.
First, we demonstrated for the first time, to our knowledge,
that using poloxamer F-127 hydrogel incorporating naked
plasmid and trypsin significantly enhanced the efficiency of
gene transfer in a rabbit vein graft model, without raising
significant safety problems. Second, we found that adven-
titial gene transfection of PD-ECGF/TP as well as vein graft
implantation resulted in significant suppression of intimal
hyperplasia at up to 8 weeks and resulted in no graft occlu-
sions. Third, mechanistically, adventitial PD-ECGF/TP gene
transfection into the vessel wall of the vein graft significantly
induced HO-1 expression and inhibited VSMC proliferation
in vivo.
Several studies have indicated that gene therapy by
transfection of the nitric oxide synthase or tissue inhibitor
of metalloproteinase genes may be effective for the treat-
ment of vascular disease, including vein graft failure.19,20
Although a number of successful results including gene
therapy have been reported to prevent intimal hyperplasia
in animals, its application is limited in cases involving vein
grafts. The main problems are the efficacy and safety of this
approach in the clinical setting.21 The use of virus vectors
has been reported in studies of experimental gene therapy
to treat vein graft failure. However, the effect of inherent
toxicity and immunogenicity of this virus prevented its
clinical application.22 Despite obvious advantages, poten-
tial clinical usefulness of naked plasmid DNA is limited
because the relatively low efficiency of gene expression with
naked DNA is not sufficient to ensure a therapeutic effect.
Poloxamer F127 is a synthetic polymer that has good
solubilizing capacity and low toxicity, and therefore is
considered a good medium for drug delivery systems.23
The poloxamer F127 solution (20% to 40%) is liquid at
colder temperatures (4° to 5°C) and gelatinous at body
temperature. This unique property allows solutions con-
taining poloxamers and other compounds to be mixed well
at colder temperatures and then solidified into a gel to
induce a slow release of the transgene into target organs at
body temperature.
Lemieux et al24 reported that the combination of two
poloxamers significantly increases gene expression of plas-
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for the first time reported that incorporation of a low
concentration of trypsin in poloxamers hydrogel signifi-
cantly promoted gene transfection into the transmural
atrium but did not induced cardiac hypertrophy or enlarge
the ventricular size. However, the precise mechanisms of
this method were unknown.
In this study we found by microscopic evaluation of the
vein graft 7 days after gene transfection under different
concentration of trypsin that the trypsin dose dependently
increased the efficiency of gene transfer and reached to
plateau from the concentration of 0.25%. Compared with
another adventitial gene delivery method that used fibrin
glue, mixed with an adenovirus vector encoding the
-galactosidase gene (with a gene transfer efficiency of
13.2%  4.6%),26 our approach obtained a higher effi-
ciency of gene transfer of about 50%. Thus, our approach
may have direct significance for clinical application. We
speculated that trypsin could degrade extracellular matrix
and promote genes infiltrating into the vessel wall. On the
other hand, trypsin can digest surface protein of cell mem-
branes, increase cellular permeability, and thus promote
gene transfection.
We have performed a number of experiments to study the
effect of PD-ECGF/TP on cardiovascular diseases.15,27-29
We used gene transfection of human PD-ECGF/TP into rat
VSMCs to study the mechanism of inhibitory effect of
PD-ECGF/TP on VSMC, and found that inhibition of
VSMC proliferation was correlated with the upregulation
of p27KIP1 and HO-1.15 We also found that adventitial
gene transfer of TP/PD-ECGF in a balloon injury rat ca-
rotid artery model markedly inhibited the intimal hyperpla-
sia. Interestingly, another group also reported that the
addition of the PD-ECGF/TP protein into the cultured
media inhibited DNA synthesis of cultured VSMCs in
vitro,30 suggesting the repeatable inhibitory effect of PD-
ECGF/TP on VSMC proliferation.
In this study, we demonstrated for the first time that
the adventitial gene transfer of PD-ECGF/TP to the vein
graft using poloxamers hydrogel significantly suppressed
the development of intimal hyperplasia. By direct assess-
ment of intima thickness and intimal areas, we found that
both of these were significantly lower in PD-ECGF/TP–
treated groups compared with the saline or LacZ groups.
The therapeutic effects could be found as early as 2 weeks
and persisted up to 8 weeks. The PCNA index of intimal
VSMCs was reduced in the pCIhTP group at 2 weeks;
however, no difference was found at 8 weeks, suggesting
that proliferative VSMC-induced intimal hyperplasia
mainly formed at the early phase after vein graft implanta-
tion. Therefore, therapy in the acute phase may play impor-
tant role in preventing for the vein graft failure. However,
further experiments need to examine the longer-term effect
of TP on vein graft intimal hyperplasia to clarify whether
this therapeutic effect is a delay in intima hypertrophy or if
it achieves a long-term inhibition. In addition, the trans-
gene and protein expression were detectable at 2 weeks, but
not at 8 weeks, suggesting that transgenic products werenot stably expressed in the graft. Therefore, the major
beneficial effects of PD-ECGF/TP on vein grafts seem to
be initiated during the first 2 weeks after the grafting.
It has been reported that endothelial dysfunction of
vein grafts and denudation contributed to vein graft failure
and damage.31,32 PD-ECGF/TP has been shown to pos-
sess significant angiogenic activity in vivo by stimulating
chemotaxis of endothelial cells.12,13,33 In our previous
study, we demonstrated the therapeutic effects of PD-
ECGF/TP gene transfer on ischemia by promoting angio-
genesis and inhibiting apoptosis (summary in Fig 5).27-29
Sengupta et al33 have reported that equimolar concentra-
tions of PD-ECGF/TP induce a similar total monolayer
recovery of wounded endothelium in vitro as well as vascu-
lar endothelial growth factor, strongly suggesting the che-
motaxis functional effect of PD-ECGF/TP on endothe-
lium. Therefore, as shown in Fig 5, we speculate that in
addition to the suppressive effect of PD-ECGF/TP on
VSMCs, PD-ECGF/TP itself, its enzymatic substrates, or
PD-ECGF/TP-derived HO-1 expression may promote
Fig 5. Scheme of effect of platelet-derived endothelial cell growth
factor/thymidine phosphorylase on vascular smooth muscle cells
(VSMC) and the endothelium. The red arrows indicate promotive
effect, and blue lines () indicates an inhibitory effect. 2-DDR-1,
2-deoxy-D-ribose 1-phosphate; HO-1, heme oxygenase-1; IL, in-
terleukin; MMP, matrix metalloproteinase; TP, thymidine phos-
phorylase; VEGF, vascular endothelial growth factor, Cyto-c, Cy-
tochrome C; Bcl-2 (anti-apoptosis) and Bax (pro-apoptosis),
members of Bcl-2 gene family; VSMC, vascular smooth muscle
cell.endothelial cell proliferation and protect endothelial cells
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clarify this hypothesis. Compared with other angiogenic
factors such as vascular endothelial growth factors and
fibroblast growth factor, which have been reported to
promote—but not initiate—intimal thickening,36 our data
indicate that PD-ECGF/TPmay be more suitable for gene
therapy to prevent vein graft failure or other ischemic
vascular diseases.
CONCLUSION
We developed a safe and highly efficient gene transfer
method by using a naked plasmid DNA mixed with polox-
amer gel and a low concentration of trypsin. Neointimal
hyperplasia was significantly reduced by adventitial applica-
tion of the PD-ECGF/TP gene to rabbit vein grafts using a
“hydrogel painting” method. Our data suggested that a
genetic approach using PD-ECGF/TP is promising for
preventing vein graft failure.
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